Kevin Yang ⎜Mar 20, 2018 ⎜ Market
99mTc-sestamibi CZT-SPECT is technically feasible and can provide similar result to 15O-water PET for detecting impaired myocardial flow reserve and abnormal fractional flow reserve in patients with coronary artery disease. This study highlights the diagnostic value of using 99mTc -sestamibi for patients with coronary artery disease.
The WATERDAY study: Denis Agostini & Vincent Roule & Catherine Nganoa & Nathaniel Roth & Raphael Baavour & Jean-Jacques Parienti & Farzin Beygui & Alain Manrique
Info on purchasing 99mTc -sestamibi, contact email@example.com
For more info on this article, please click here.
Kevin Yang ⎜Mar 12, 2018 ⎜ Market
Osteoclast activity is an important factor in the pathogenesis of skeletal metastases and is a potential therapeutic target. This study aimed to determine if selective uptake of 99mTc-maraciclatide, a radiopharmaceutical targeting αvβ3 integrin, occurs in prostate cancer (PCa) bone metastases and to observe the changes following systemic therapy.
Conclusion: 99mTc-maraciclatide accumulates in PCa bone metastases in keeping with increased αvβ3 integrin expression. Greater activity in metastases with lower CT density suggests that uptake is related to osteoclast activity. Changes in planar and SPECT T:M ratios after 12 weeks of treatment differed between patients with and without PD and 99mTc-maraciclatide imaging may be a potential method for assessing early response.
Cook, G.J.R., Azad, G.K., Taylor, B.P. et al. Eur J Nucl Med Mol Imaging (2018).
For full article, please access: